a phase 2 trial using tranglutaminase 2 inhibitor in celiac disease significant improvement in villous height to crypt depth among intervention group compared to placebo group.
The American college of gastroenterology had published the latest UGIB guidelines in January 2021. Although much has not changed, they have considered new evidence from RCT’s published in the last 5 years to make these recommendations.
SARS-CoV2, first started at Wuhan province, china has spread throughout the world, leading to a pandemic, the science here is evolving daily, with new molecules discovered every day and scientists scrambled to investigate new therapies.
we all know the patients with GERD, most of them are dependant on Proton pump inhibitors (PPI), there are surgeries for these patients who have inadequate response to PPI, how ever, their symptoms usually relapse after 5 to 10 years of surgery.